n.a. (PCYC)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

Today's spike in oil prices was even strong enough to embolden money managers to do some buying, Cramer says.

The Amazing Thing About the Receptos Takeover Chatter

That this could be such an open secret is beyond me.

AXON, REGN, BURL, FIVE: Jim Cramer's Views

AXON, REGN, BURL, FIVE: Jim Cramer's Views

Jim Cramer shares his views on the latest moves in biotech and retail. Account, Regeneron, Burlington Stores and Five Below are among the many stocks discussed here.

The 10 Biggest U.S. M&A Deals in 2015

The 10 Biggest U.S. M&A Deals in 2015

Health care deals dominate the list of big mergers so far this year, while tech comes in second.

Biotech Moves Are Anything But Crazy

New companies are coming up with major drugs.

Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck

Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck

Jim Cramer likes the 10 early-stage drugs J&J has in its pipeline, among other reasons.

Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas

Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas

Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.

New Lifetime High For Pharmacyclics (PCYC)

New Lifetime High For Pharmacyclics (PCYC)

Trade-Ideas LLC identified Pharmacyclics (PCYC) as a new lifetime high candidate

Deluge of Deals Isn't About to Dry Up

Acquisitions cut into overabundance of companies.

3 Biotechs That Are Worth Buying

Many of these stocks are off to the races.

Jim Cramer -- Why Is Janet Yellen Suddenly a Stock Commentator?

Jim Cramer -- Why Is Janet Yellen Suddenly a Stock Commentator?

The Fed chief used some pretty frightening terms about stocks Wednesday, saying that valuations 'generally are quite high' and that there are 'potential dangers' with them.

Janet Yellen, Stock Market Commentator?

It's not the Fed chief's place.

First-Quarter Deals Near $1 Trillion Mark Highest Value Since 2007

First-Quarter Deals Near $1 Trillion Mark Highest Value Since 2007

Mega deals from strategic players across a variety of industries pushed first-quarter deals to the highest value since 2007.

Earnings Growth Boosts AbbVie

Drug franchises are still going strong.

Jim Cramer -- Mylan's Move to Acquire Perrigo a Prescription for Success

Jim Cramer -- Mylan's Move to Acquire Perrigo a Prescription for Success

The drug companies' strengths in generics and knocks-off drugs should complement one another.

Mylan Bids $29 Billion for Perrigo in Latest Big Pharma Deal

Mylan Bids $29 Billion for Perrigo in Latest Big Pharma Deal

Mylan made public on Wednesday that it had made a proposal to acquire generic drugmaker Perrigo in a deal valued at $205 per share in cash and stock.

Mylan Deal Is All That Shell Is Not

The ecstasy and the agony of M&A all in one day.

Portfolio Managers Shop for Growth

Combined Heinz-Kraft heads a long second-quarter list.

Biotech Merger Monday Doesn't Squash Biotech Bubble Debate

Biotech Merger Monday Doesn't Squash Biotech Bubble Debate

Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.

Biotech, Chips Stand Their Ground; Be Careful What You Wish For: Jim Cramer's Best Blogs

Biotech, Chips Stand Their Ground; Be Careful What You Wish For: Jim Cramer's Best Blogs

Catch up on Jim Cramer's thinking over the last week about two leadership groups that have been hammered and the spike in oil.

Biotech, Chips Stand Their Ground

You can't help but feel better about both groups.

BioMarin Rises Amid Takeover Speculation, Price Target Raises

BioMarin Rises Amid Takeover Speculation, Price Target Raises

The shares of BioMarin are climbing after a blog reported last night that Shire is considering offering to acquire the company.

Biotechs Need to Rest

If there is no catalyst, I'd join those who sell on a bounce.

3 Stocks Reiterated As A Hold: PCYC, LNKD, PM

3 Stocks Reiterated As A Hold: PCYC, LNKD, PM

TheStreet Ratings team reiterated 3 stocks with a hold rating on Thursday

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

If history repeats itself, the recent weakness in biotech stocks will end with lots more buying.

Backing Away From Biotechs

This sector could see some real damage.

The 7 Pillars of Healthcare Strength

Here are healthcare stocks of all shares and sizes with strong charts.

Biotech Stocks at a Crossroad

Own them, or take something off the table?